In human cutaneous T-cell lymphoma, the downregulation of survivin, a key inhibitor of apoptosis, following XPO1 inhibition may lower the cellular threshold for apoptosis, enhancing the drug sensitivity. This evidence concerns the gene XPO1 and primary cutaneous T-cell non-Hodgkin lymphoma.